Role of Suppressor of Cytokine Signaling 3 in the Immune Modulation of Mesenchymal Stromal Cells
- 307 Downloads
The underlying mechanisms of mesenchymal stromal cells (MSCs) on immune modulation to treat allergic diseases remain unclear. Here, we showed that the suppressor of cytokine signaling 3 (SOCS3) is an important immune modulator expressed by MSCs, which is significantly increased by interferon-γ (IFN-γ). In addition, we observed that SOCS3 is a crucial mediator of the anti-proliferative and functional effects of MSCs on T cells and B cells. The immune modulation of MSCs through SOCS3 is mediated by cell–cell contacts. Moreover, SOCS3 could serve as an indicator to predict the potential immune modulatory of MSCs derived from different donors. Furthermore, treatment with anti-SOCS3 Ab significantly decreased ovalbumin-specific antibodies and neutrophil infiltration in ovalbumin-induced allergic rhinitis (AR) mice. Our results suggest that SOCS3 serves as an immune modulator interfering with T cells and B cells, and SOCS3 may act as a predictive marker for immune modulatory of MSCs.
KEY WORDSSOCS3 mesenchymal stromal cells immune modulatory interferon-γ
This work was supported by grants from the National Natural Science Foundation of China (Nos. 81470672).
Conflicts of Interest
The authors declare no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 20.Rodrigo, S.F., J. van Ramshorst, G.E. Hoogslag, H. Boden, M.A. Velders, S.C. Cannegieter, et al. 2013. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. Journal of Cardiovascular Translational Research 6: 816–825.PubMedCentralCrossRefPubMedGoogle Scholar
- 24.Battula, V.L., P.M. Bareiss, S. Treml, S. Conrad, I. Albert, S. Hojak, et al. 2007. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 75: 279–291.CrossRefPubMedGoogle Scholar
- 32.Ungerer, C., P. Quade-Lyssy, H.H. Radeke, R. Henschler, C. Konigs, U. Kohl, et al. 2014. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells and Development 23: 755–766.PubMedCentralCrossRefPubMedGoogle Scholar
- 34.Kinjyo, I., H. Inoue, S. Hamano, S. Fukuyama, T. Yoshimura, K. Koga, et al. 2006. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. Journal of Experimental Medicine 203: 1021–1031.PubMedCentralCrossRefPubMedGoogle Scholar
- 42.Li, Y.P., S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, et al. 2008. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. Journal of Immunology 180: 1598–1608.CrossRefGoogle Scholar